Mannitol Use During Cadaveric Kidney Transplantation

• Status: Not yet recruiting
• Trial end date: 2022-02-01
• Target enrollment: 0
• Participant gender: All

Summary

We propose a placebo controlled randomized study on the use of mannitol as an agent to protect against delayed graft function, during the surgical procedure of kidney transplantation from a cadaver. Patients undergoing kidney transplantation for the treatment of end stage kidney disease will be randomized in a ratio of 1:1 to receive either intravenous mannitol or saline during their procedure, administered prior to renal artery clamp release and reperfusion of the kidney. Changes in renal function following surgery and the incidence and duration of delayed graft function (DGF) will be monitored using calculated glomerular filtration rate (eGFR) and the need for dialysis performed post-operatively, as part of routine standard of care. Additionally biological samples will be collected and analyzed for use of a non invasive biomarker for delayed graft function.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rabin Medical Center
• Treatments: Mannitol

Criteria

Inclusion Criteria:

• Age >18 years

• Patients on the list of cadaveric donor kidney transplantation

Exclusion Criteria:

• Allergy to mannitol

• Allergy to furosemide

• Combined major surgical cases that may include transplantation of another organ on the same time, such as liver.

• Severe congestive heart failure (ejection fraction < 30%)

• Patients with coagulation disorders.

• Patients who are not able to sign an informed consent